Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer

NCT02768558 is registered in ClinicalTrials.gov with RTOG Foundation, Inc. as lead sponsor.

NCT NCT02768558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02768558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Lead sponsor
RTOG Foundation, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
October 17, 2016
Completion date
January 23, 2019
Enrollment
20 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer